A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in ...

Treatment with the investigational oral, allosteric, selective AKT inhibitor engasertib appeared to be safe in patients with ...

Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in ...

LAFFAYETTE, NJ – A local family has taken their personal story and turned it into a fundraising event. Sparta High School Athletic Director Steve Stoner’s uncle has a blood disorder known as HHT. They ...

Please provide your email address to receive an email when new articles are posted on . Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated ...

WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, today announced they will ...